12:00 AM
Jun 17, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Alliance Pharma, Novartis sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired all rights to Syntometrine oxytocin/ergometrine from Novartis for $11.5 million. Alliance already had rights to the product in the U.K. under a 2006 deal. The...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >